Yamashita, Shizuya

Paradoxical Decrease of an Adipose-Specific Protein, Adiponectin, in Obesity

Arita, Y., Kihara, S., Ouchi, N., Takahashi, M., Maeda, K., Miyagawa, J.-I., Hotta, K., Shimomura, I., Nakamura, T., Miyaoka, K., et al. (1999) · Biochemical and Biophysical Research Communications

Adipokines, Inflammation, and Metabolic DiseasesAdipose Tissue and Metabolism

Cited by 4,856

Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity

Ross, R., Neeland, I. J., Yamashita, S., Shai, I., Seidell, J., Magni, P., Santos, R. D., Arsenault, B., Cuevas, A., Hu, F. B., et al. (2020) · Nature Reviews Endocrinology

Diabetes, Cardiovascular Risks, and LipoproteinsBody Composition Measurement Techniques

Cited by 1,966

Visfatin: A Protein Secreted by Visceral Fat That Mimics the Effects of Insulin

Fukuhara, A., Matsuda, M., Nishizawa, M., Segawa, K., Tanaka, M., Kishimoto, K., Matsuki, Y., Murakami, M., Ichisaka, T., Murakami, H., et al. (2005) · Science

Adipokines, Inflammation, and Metabolic DiseasesAdipose Tissue and Metabolism

Cited by 1,906

Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement

Neeland, I. J., Ross, R., Després, J.-P., Matsuzawa, Y., Yamashita, S., Shai, I., Seidell, J., Magni, P., Santos, R. D., Arsenault, B., et al. (2019) · The Lancet Diabetes & Endocrinology

Cardiovascular Disease and AdiposityDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 1,603

Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017

Kinoshita, M., Yokote, K., Arai, H., Iida, M., Ishigaki, Y., Ishibashi, S., Umemoto, S., Egusa, G., Ohmura, H., Okamura, T., et al. (2018) · Journal of Atherosclerosis and Thrombosis

Lipoproteins and Cardiovascular HealthHealth Promotion and Cardiovascular Prevention

Cited by 813

Angiopoietin-Like Protein3 Regulates Plasma HDL Cholesterol Through Suppression of Endothelial Lipase

Shimamura, M., Matsuda, M., Yasumo, H., Okazaki, M., Fujimoto, K., Kono, K., Shimizugawa, T., Ando, Y., Koishi, R., Kohama, T., et al. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology

Lipid metabolism and disordersCholesterol and Lipid Metabolism

Cited by 297

Genetic Cholesteryl Ester Transfer Protein Deficiency Is Extremely Frequent in the Omagari Area of Japan: Marked Hyperalphalipoproteinemia Caused by CETP Gene Mutation Is Not Associated With Longevity

Hirano, K.-I., Yamashita, S., Nakajima, N., Arai, T., Maruyama, T., Yoshida, Y., Ishigami, M., Sakai, N., Kameda-Takemura, K., & Matsuzawa, Y. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology

Lipoproteins and Cardiovascular HealthParaoxonase enzyme and polymorphisms

Cited by 275

Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized, Controlled Trial

Ouchi, Y., Sasaki, J., Arai, H., Yokote, K., Harada, K., Katayama, Y., Urabe, T., Uchida, Y., Hayashi, M., Yokota, N., et al. (2019) · Circulation

Lipoproteins and Cardiovascular HealthBlood Pressure and Hypertension Studies

Cited by 231

Retraction

Fukuhara, A., Matsuda, M., Nishizawa, M., Segawa, K., Tanaka, M., Kishimoto, K., Matsuki, Y., Murakami, M., Ichisaka, T., Murakami, H., et al. (2007) · Science

Cited by 150

Postprandial Hyperlipidemia and Remnant Lipoproteins

Masuda, D., & Yamashita, S. (2017) · Journal of Atherosclerosis and Thrombosis

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 145

Long-Term Probucol Treatment Prevents Secondary Cardiovascular Events: a Cohort Study of Patients with Heterozygous Familial Hypercholesterolemia in Japan

Yamashita, S., Bujo, H., Arai, H., Harada-Shiba, M., Matsui, S., Fukushima, M., Saito, Y., Kita, T., & Matsuzawa, Y. (2008) · Journal of Atherosclerosis and Thrombosis

Lipoproteins and Cardiovascular HealthParaoxonase enzyme and polymorphisms

Cited by 110

Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: An analysis of more than 33,000 high cardiovascular risk patients in Japan

Teramoto, T., Uno, K., Miyoshi, I., Khan, I., Gorcyca, K., Sanchez, R. J., Yoshida, S., Mawatari, K., Masaki, T., Arai, H., et al. (2016) · Atherosclerosis

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 71

Impaired Insulin Secretion in Four Tangier Disease Patients with ABCA1 Mutations

Koseki, M., Matsuyama, A., Nakatani, K., Inagaki, M., Nakaoka, H., Kawase, R., Yuasa-Kawase, M., Tsubakio-Yamamoto, K., Masuda, D., C. Sandoval, J., et al. (2009) · Journal of Atherosclerosis and Thrombosis

Pancreatic function and diabetesLipid metabolism and disorders

Cited by 65

Disappearance of intraglomerular lipoprotein thrombi and marked improvement of nephrotic syndrome by bezafibrate treatment in a patient with lipoprotein glomerulopathy

Arai, T., Yamashita, S., Yamane, M., Manabe, N., Matsuzaki, T., Kiriyama, K., Kanayama, Y., Himeno, S., & Matsuzawa, Y. (2003) · Atherosclerosis

Renal Diseases and GlomerulopathiesLipid metabolism and disorders

Cited by 43

Accelerated Atherogenicity in Tangier Disease: A Case Accompanied by Extensive Atherosclerotic Lesions, Leriche Syndrome and Bleeding Tendency, and Review of the Literature

Muratsu, J., Koseki, M., Masuda, D., Yasuga, Y., Tomoyama, S., Ataka, K., Yagi, Y., Nakagawa, A., Hamada, H., Fujita, S., et al. (2018) · Journal of Atherosclerosis and Thrombosis

Cholesterol and Lipid MetabolismLipoproteins and Cardiovascular Health

Cited by 27

Efficacy, Safety, and Pharmacokinetics of Inclisiran in Japanese Patients: Results from ORION-15

Yamashita, S., Kiyosue, A., Maheux, P., Mena-Madrazo, J., Lesogor, A., Shao, Q., Tamaki, Y., Nakamura, H., Akahori, M., & Kajinami, K. (2024) · Journal of Atherosclerosis and Thrombosis

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 26

Lessons from PROMINENT and prospects for pemafibrate

Fruchart, J.-C., Fruchart-Najib, J., Yamashita, S., Libby, P., Yokote, K., Kodama, T., Tomita, Y., Ridker, P. M., Hermans, M. P., & Zambon, A. (2024) · Cardiovascular Diabetology

Peroxisome Proliferator-Activated ReceptorsLiver Disease Diagnosis and Treatment

Cited by 16

Distinct Differences in Lipoprotein Particle Number Evaluation between GP-HPLC and NMR: Analysis in Dyslipidemic Patients Administered a Selective PPARα Modulator, Pemafibrate

Yamashita, S., Okazaki, M., Okada, T., Masuda, D., Yokote, K., Arai, H., Araki, E., & Ishibashi, S. (2021) · Journal of Atherosclerosis and Thrombosis

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 14

A Pooled Analysis of Pemafibrate Phase II/III Clinical Trials Indicated Significant Improvement in Glycemic and Liver Function-related Parameters

Yokote, K., Yamashita, S., Arai, H., Araki, E., Suganami, H., & Ishibashi, S. (2018) · Atherosclerosis Supplements

Lipoproteins and Cardiovascular HealthMicroRNA in disease regulation

Cited by 11

Effects of Selective PPARα Modulator K-877 on Particle Numbers of Lipoprotein Subclasses in Dyslipidemic Patients: Analysis by GP-HPLC and NMR Lipoprofile 2 and 3

Yamashita, S., Okazaki, M., Okada, T., Masuda, D., Arai, H., Yokote, K., Araki, E., & Ishibashi, S. (2018) · Atherosclerosis Supplements

Lipoproteins and Cardiovascular HealthPeroxisome Proliferator-Activated Receptors

Cited by 2